Literature DB >> 29273476

Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.

Bing Xu1, Mingzuo Jiang1, Yi Chu1, Weijie Wang1, Di Chen1, Xiaowei Li1, Zhao Zhang2, Di Zhang1, Daiming Fan1, Yongzhan Nie1, Feng Shao3, Kaichun Wu4, Jie Liang5.   

Abstract

BACKGROUND & AIMS: Gasdermin D (GSDMD)-executed programmed necrosis is involved in inflammation and controls interleukin (IL)-1β release. However, the role of GSDMD in non-alcoholic steatohepatitis (NASH) remains unclear. We investigated the role of GSDMD in the pathogenesis of steatohepatitis.
METHODS: Human liver tissues from patients with non-alcoholic fatty liver disease (NAFLD) and control individuals were obtained to evaluate GSDMD expression. Gsdmd knockout (Gsdmd-/-) mice, obese db/db mice and their wild-type (WT) littermates were fed with methionine-choline deficient (MCD) or control diet to induce steatohepatitis. The Gsdmd-/- and WT mice were also used in a high-fat diet (HFD)-induced NAFLD model. In addition, Alb-Cre mice were administered an adeno-associated virus (AAV) vector that expressed the gasdermin-N domain (AAV9-FLEX-GSDMD-N) and were fed with either MCD or control diet for 10 days.
RESULTS: GSDMD and its pyroptosis-inducing fragment GSDMD-N were upregulated in liver tissues of human NAFLD/NASH. Importantly, hepatic GSDMD-N protein levels were significantly higher in human NASH and correlated with the NAFLD activity score and fibrosis. GSDMD-N remained a potential biomarker for the diagnosis of NASH. MCD-fed Gsdmd-/- mice exhibit decreased severity of steatosis and inflammation compared with WT littermates. GSDMD was associated with the secretion of pro-inflammatory cytokines (IL-1β, TNF-α, and MCP-1 [CCL2]) and persistent activation of the NF-ĸB signaling pathway. Gsdmd-/- mice showed lower steatosis, mainly because of reduced expression of the lipogenic gene Srebp1c (Srebf1) and upregulated expression of lipolytic genes, including Pparα, Aco [Klk15], Lcad [Acadl], Cyp4a10 and Cyp4a14. Alb-Cre mice administered with AAV9-FLEX-GSDMD-N showed significantly aggravated steatohepatitis when fed with MCD diet.
CONCLUSION: As an executor of pyroptosis, GSDMD plays a key role in the pathogenesis of steatohepatitis, by controlling cytokine secretion, NF-ĸB activation, and lipogenesis. LAY
SUMMARY: Non-alcoholic fatty liver disease has become one of the most feared chronic liver diseases, because it is the most rapidly growing indication for adult liver transplantation and a major cause of hepatocellular carcinoma. However, the mechanisms involved in the transformation of simple steatosis to steatohepatitis remain unclear. Herein, we show that gasdermin D driven pyroptosis is prominent in patients with non-alcoholic steatohepatitis (NASH), and gasdermin-N domain remains a potential biomarker for the diagnosis of NASH. Gasdermin D plays a key role in the pathogenesis of NASH by regulating lipogenesis, the inflammatory response, and the NF-ĸB signaling pathway, revealing potential treatment targets for NASH in humans.
Copyright © 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  GSDMD; GSDMD-N; NF-ĸB; Non-alcoholic steatohepatitis; Pyroptosis

Mesh:

Substances:

Year:  2017        PMID: 29273476     DOI: 10.1016/j.jhep.2017.11.040

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  101 in total

1.  Pyroptosis: An inflammatory link between NAFLD and NASH with potential therapeutic implications.

Authors:  Juliane I Beier; Jesus M Banales
Journal:  J Hepatol       Date:  2018-02-14       Impact factor: 25.083

Review 2.  Use of Tripterygium wilfordii Hook F for immune-mediated inflammatory diseases: progress and future prospects.

Authors:  Cong-Ying Song; Ying-Ge Xu; Yuan-Qiang Lu
Journal:  J Zhejiang Univ Sci B       Date:  2020 Apr.       Impact factor: 3.066

3.  The Role of NF-κB/NLRP3 Inflammasome Signaling Pathway in Attenuating Pyroptosis by Melatonin Upon Spinal Nerve Ligation Models.

Authors:  Yi-Hao Wang; Xiao Gao; Yu-Ru Tang; Yang Yu; Ming-Jie Sun; Fu-Qiang Chen; Yan Li
Journal:  Neurochem Res       Date:  2021-09-13       Impact factor: 3.996

Review 4.  Lytic cell death in metabolic liver disease.

Authors:  Jérémie Gautheron; Gregory J Gores; Cecília M P Rodrigues
Journal:  J Hepatol       Date:  2020-04-13       Impact factor: 25.083

5.  PTUPB ameliorates high-fat diet-induced non-alcoholic fatty liver disease via inhibiting NLRP3 inflammasome activation in mice.

Authors:  Chen-Chen Sun; Chen-Yu Zhang; Jia-Xi Duan; Xin-Xin Guan; Hui-Hui Yang; Hui-Ling Jiang; Bruce D Hammock; Sung Hee Hwang; Yong Zhou; Cha-Xiang Guan; Shao-Kun Liu; Jun Zhang
Journal:  Biochem Biophys Res Commun       Date:  2020-01-20       Impact factor: 3.575

Review 6.  The emerging roles of inflammasome-dependent cytokines in cancer development.

Authors:  Hanne Van Gorp; Mohamed Lamkanfi
Journal:  EMBO Rep       Date:  2019-05-17       Impact factor: 8.807

Review 7.  From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases.

Authors:  Peng Zhao; Alan R Saltiel
Journal:  J Biol Chem       Date:  2020-07-10       Impact factor: 5.157

8.  Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.

Authors:  Susanne Gaul; Aleksandra Leszczynska; Fernando Alegre; Benedikt Kaufmann; Casey D Johnson; Leon A Adams; Alexander Wree; Georg Damm; Daniel Seehofer; Carolina J Calvente; Davide Povero; Tatiana Kisseleva; Akiko Eguchi; Matthew D McGeough; Hal M Hoffman; Pablo Pelegrin; Ulrich Laufs; Ariel E Feldstein
Journal:  J Hepatol       Date:  2020-08-04       Impact factor: 25.083

9.  Inflammation and tumor progression: signaling pathways and targeted intervention.

Authors:  Huakan Zhao; Lei Wu; Guifang Yan; Yu Chen; Mingyue Zhou; Yongzhong Wu; Yongsheng Li
Journal:  Signal Transduct Target Ther       Date:  2021-07-12

Review 10.  Immunopathobiology and therapeutic targets related to cytokines in liver diseases.

Authors:  Yong He; Seonghwan Hwang; Yeni Ait Ahmed; Dechun Feng; Na Li; Marcelle Ribeiro; Fouad Lafdil; Tatiana Kisseleva; Gyongyi Szabo; Bin Gao
Journal:  Cell Mol Immunol       Date:  2020-11-17       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.